Phase 3 Chronic Kidney Disease Trial, Recruiting NCT05546099 Sponsor: VA Office of Research and Development Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT05546099
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have moderate-to-moderately-severe kidney disease (known as CKD stage 3 or 4), where the kidneys are filtering at a reduced but not critically low level
  • People who have mild kidney disease (CKD stage 2) with high levels of a protein called albumin leaking into the urine — the specific threshold depends on whether or not the person also has diabetes
  • People whose blood pressure is not well controlled, meaning the average of two blood pressure readings shows the top number is above 140

Who may not be able to join:

  • People whose blood pressure is severely out of control, with the top number above 180
  • People whose high blood pressure has not responded to treatment and who are already taking four blood pressure medications
  • People who experience a significant drop in blood pressure when standing up (for example, feeling dizzy or faint after rising from a seated or lying position)
  • People with very severe kidney disease, where the kidneys are filtering at a critically low level
  • People with a life expectancy of less than one year
  • People with severe liver disease
  • People with severe heart failure
  • People with severe memory or thinking problems caused by dementia
  • People who are pregnant, breastfeeding, or unwilling to use reliable contraception during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Diana Jalal, MD, Iowa City VA Health Care System, Iowa City, IA

Phone: (319) 338-0581

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
15 December 2022
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in standardized office BP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov